32431-30-4

Usage

Uses

Used in Pharmaceutical Industry:
6-CHLORO-2-HYDROXY-QUINOLINE-4-CARBOXYLIC ACID is used as a key intermediate in the synthesis of various medicinally active compounds. Its anti-microbial and anti-inflammatory properties contribute to the development of drugs for treating a range of diseases, enhancing therapeutic options for patients.
Used in Agrochemical Production:
6-CHLORO-2-HYDROXY-QUINOLINE-4-CARBOXYLIC ACID is also utilized in the production of agrochemicals, where its anti-microbial properties can be harnessed to create products that protect crops and enhance agricultural yields.
Used in Dye Manufacturing:
6-CHLORO-2-HYDROXY-QUINOLINE-4-CARBOXYLIC ACID finds application in the manufacturing of dyes due to its chemical structure, which allows for the creation of diverse colorants used in various industries.

Upstream product

• 126719-06-0 1-acetyl-5-chloro-1H-indole-2,3-dione 
• 17630-76-1 5-chloroindole 2,3-dione 
• 2585-04-8 6-chloro-4-methyl-quinolin-2-ol 
• 101-92-8 4'-Chloroacetoacetanilide 
• 141-82-2 malonic acid 

Relevant academic research and scientific papers

QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present disclosure provides novel compounds, compositions comprising the compounds and methods of use thereof.

Discovery, synthesis and molecular substantiation of N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides as anticancer agents

The effort was taken to develop a series of benzothiazole and quinoline fused bioactive compounds obtained through a four-step synthetic route using a range of substituted acetoacetanilides. Achieved N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides (6a-l) were produced up to 96% of yield while the eco-friendly p-TSA used as a catalyst. Further, the anticancer activity of these compounds was determined using a range of cancer cell lines starting from MCF-7 (Breast cancer), HCT-116 (Colon cancer), PC-3 & LNCaP (Prostate) and SK-HEP-1 (Liver cancer). Present study compounds were also testified for antioxidant properties prior to anticancer studies since the Reactive Oxygen Species (ROS) being vital in cancer development. To determine the cell membrane stability effects of the compounds, human red blood cells (HRBC) based membrane protection assay was determined. In the results, compounds 6a-l were able to produce a dominated result values over PC3 cell lines (Prostate cancer) than the other cell lines used in this study. Since the connectivity of human germ cell alkaline phosphatase (hGC-ALP) in the development of prostate cancer is known, the most active compounds were evaluated for the hGC-ALP inhibition in order to ensure a mechanism of anticancer action of these compounds. The mode of interaction and binding affinity of these compounds was also investigated by a molecular docking study. In the results, 6d, 6i, 6k, and 6l were found with least IC50 values 0.075 μM and highest relative activity of 92%, 90%, and 96% respectively. The need for further animal model evaluation and pre-clinical studies recognized.

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC50 = 120 nM) was optimized to lead molecules with low nanomolar in vitro potency. Improvement of the pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency, selectivity, DMPK properties, and efficacy coupled with a novel mechanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498) to preclinical development.

Anti-Malarial Agents

The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

ANTI-MALARIAL AGENTS

The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

Use of imidazo?1,5-a!quinolones as neuroprotective agents

The imidazo?1,5-a!quinolines (I) are useful in treating neurological diseases/conditions or chronic neurodegenerative diseases/conditions.

Imidazo[1,5-A]quinolines for treatment of anxiety and sleep disorders

Imidazo[1,5-a]quinolines of formula (I) which are useful pharmaceutical agents for the treatment of anxiety, sleep disorders, panic states, convulsions and muscle disorders. STR1